Ken Grime

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades.

Susanne Winiwarter, Rhys D O Jones, Michael Davies, 2020, Trends in pharmacological sciences.

The evolving nature of university campus safety in Australia

Ken Grime, Lisa Jane Warren, K. Grime, 2016 .

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Ken Grime, R. Riley, Robert J. Riley, 2007, Drug Metabolism and Disposition.

Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and HepaRG

Ken Grime, Ia Hultman, Petter Svanberg, 2016, Drug Metabolism and Disposition.

The discovery of AZD9164, a novel muscarinic M3 antagonist.

Keith Bowers, Ken Grime, Helen Edwards, 2011, Bioorganic & medicinal chemistry letters.

Optimisation of DMPK by the inhaled route: challenges and approaches.

Ken Grime, Douglas Ferguson, K. Grime, 2012, Current drug metabolism.

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Melvin E. Andersen, Harvey J. Clewell, Thierry Lavé, 2007 .

Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement

Ken Grime, S. Paine, K. Grime, 2013, Drug Metabolism and Disposition.

Time-dependent CYP inhibition

Robert J Riley, Ken Grime, Richard Weaver, 2007, Expert opinion on drug metabolism & toxicology.